Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

541
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
541
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

387
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scoping Review of Global Kidney Genetics Clinic Models and Outcomes.

Kidney international reports·2026
Same author

Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Automated reanalysis of genomic data for rare disease diagnostics at scale.

Nature medicine·2026
Same author

Autosomal Dominant Polycystic Kidney Disease: Genetic Insights, Phenotypic Spectrum, and Advances in Prognosis and Treatment.

Advances in kidney disease and health·2026
Same author

A cluster randomized controlled trial (GOAL trial) evaluated a comprehensive geriatric assessment for frail older people with chronic kidney disease.

Kidney international·2026
Same author

Long-Read Sequencing in CKD Diagnostics: Breaking Genomic Barriers and Expanding Global Inclusion.

Kidney international reports·2026
Same journal

Urinary Soluble CD163: A Dynamic Biomarker for Monitoring Treatment Response and Relapse in IgA Nephropathy.

Kidney international reports·2026
Same journal

<i>APOL1</i> Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

Kidney international reports·2026
Same journal

Validation of the Standardized Outcomes in Nephrology - Life Participation (SONG-LP) Instrument in People Receiving Dialysis.

Kidney international reports·2026
Same journal

Effect of Hemodialysis With Citrate on Vascular Calcification.

Kidney international reports·2026
Same journal

Diagnostic Latency and Unmeasured Disease Severity in Male Lupus Nephritis.

Kidney international reports·2026
Same journal

Antinephrin, Antipodocin, and Anti-Kirrel1 Autoantibodies in Posttransplant Recurrent FSGS.

Kidney international reports·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K

End Point Selection in ADPKD Clinical Trials.

Kitty St Pierre1,2, Ragada El-Damanawi3, Julia Jefferis4,5

  • 1Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Kidney International Reports
|November 24, 2025
PubMed
Summary
This summary is machine-generated.

Developing clinical trial endpoints for Autosomal dominant polycystic kidney disease (ADPKD) is challenging due to slow, variable progression. Novel trial designs may offer solutions for outcome selection in ADPKD research.

Keywords:
autosomal dominant polycystic kidney diseaseclinical trialsend pointoutcomes

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.3K

Related Experiment Videos

Last Updated: Jan 10, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.3K

Area of Science:

  • Nephrology
  • Clinical Trials
  • Genetics

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) is a primary genetic cause of kidney failure.
  • Clinical trial endpoint development for ADPKD faces significant hurdles due to disease heterogeneity and slow progression.

Purpose of the Study:

  • To explore challenges in selecting clinical trial endpoints for ADPKD.
  • To examine how modern trial designs can address these challenges.
  • To provide an overview of commonly reported outcomes in ADPKD trials.

Main Methods:

  • Review of ADPKD progression characteristics.
  • Analysis of limitations of traditional clinical endpoints (e.g., death, kidney failure).
  • Evaluation of surrogate outcomes (e.g., GFR, kidney volume) and their validity.
  • Exploration of alternative trial designs (e.g., population enrichment) and novel approaches.

Main Results:

  • Traditional endpoints in ADPKD trials require large sample sizes and long follow-up due to infrequent and late occurrence.
  • Surrogate outcomes show variable validity across different ADPKD patient populations.
  • Enriching trial populations with high-risk individuals can mitigate challenges but limits generalizability.

Conclusions:

  • Novel trial designs offer potential solutions to overcome difficulties in outcome selection for ADPKD clinical trials.
  • Careful consideration of trial design and outcome measures is crucial for advancing ADPKD research and therapeutic development.